The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...

Patients received 35 cycles of intravenous atezolizumab and obinutuzumab, a CD20-targeting monoclonal ... with 25% having received a BTK inhibitor only, 32% chemoimmunotherapy, and the rest ...

Susac syndrome is a rare inflammatory vascular endotheliopathy affecting the small vessels of the brain, eye, and ear.1,2 ...

One rival to Imjudo/Imfinzi in previously untreated HCC is Roche's dual regimen of PD-L1 inhibitor Tecentriq (atezolizumab) and CD20-targeting antibody Avastin (bevacizumab), which was approved by ...

ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ETCompany ParticipantsThomas Kudsk - IRJiwon Oh - MD, PhD, St.

The US regulator has placed oral BTK inhibitor orelabrutinib on partial ... That could give the drugs an advantage over CD20-targeting therapies like Roche's Ocrevus (ocrelizumab) that inhibit ...

Antibodies against B cells Rituximab is a depleting antibody directed against CD20 on the surface of B ... risk of infections and malignancies. TNF-inhibitors have several different safety issues ...

We now have potent drugs that nearly completely suppress relapses, and anti-CD20 monoclonal antibodies are particularly ...